Analyst Research Report Snapshot


EPZM - Epizyme Inc - Downgraded to a Sell - Company Analysis and ASR Ranking Report




Alpha Street Research


07 May 2014





Companies referenced:


Available for Immediate Download
Summary: - Full Coverage of 3,000 U.S. equities. Reports include Financials, Ratios, Competitor Comparison, and our proprietary ASR Ranking indicating Buy/Sell/Hold. Epizyme, Inc. develops and discovers therapeutics for the treatment of cancer. The Company provides small molecule inhibitors for patients with genetically-defined cancers, and inflammatory, metabolic, and neurodegenerative diseases. Epizyme operates in the United States.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.